Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

This study has been terminated.
(The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in patients with refractory prostate and lymphoma)
Information provided by (Responsible Party):
Astex Pharmaceuticals Identifier:
First received: February 19, 2009
Last updated: December 1, 2011
Last verified: December 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2010
  Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)